 4. Patients with prior treatment with a cumulative dose of doxorubicin or equivalent exceeding 300 mgm2 according to the following calculation index: X300 Y160 1 where X is the doxorubicin or equivalent dose in mgm2 and Y is the mitoxantrone dose in mgm2. These calculations are to be used as guidance as there is no maximum cumulative dose defined in the summary of product characteristics SPC for idarubicin. The patient should tolerate minimum one course of combination therapy 